Skip to main content
SpringerLink
Log in

Circulating tumor markers in breast cancer: Accepted utilities and novel prospects

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Detecting and/or monitoring changes in circulating tumor markers might assist in evaluating cancer risk, diagnosis, prognosis, or response to treatment. Several categories of circulating tumor markers have been investigated in breast cancer. These categories include classical tumor-associated antigens, such as CEA and CA 15-3, markers of tumor biology, including markers of angiogenesis, adhesion, and invasion, and antibody response to tumor-associated antigens such as HER2/neu and p53. We used a recently proposed Tumor Marker Utility Grading System to evaluate the use of several circulating tumor markers for different clinical utilities in breast cancer. While there are no tumor markers with established clinical utilities for most uses, tumor-associated antigens can be used for monitoring patients with metastatic disease. In addition, markers of tumor biology such as the circulating extracellular domain of HER2/neu might be useful in determining not only prognosis, but also response to specific treatments. However, further investigations are required to further assess the utility of individual tumor markers for specific clinical uses.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hayes DF, Bast R, Desch CE, Fritsche H, Kemeny NE, Jessup J, Locker GY, Macdonald J, Mennel RG, Norton L, Ravdin P, Taube S, Winn R: A tumor marker utility grading system (TMUGS): a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88:1456-1466, 1996

    Google Scholar 

  2. Sell S: Cancer markers of the 1990s: An introduction. In: Sell S (ed) Serological Cancer Markers. Humana Press, Totowa NJ, 1992, pp 1-17

    Google Scholar 

  3. Morelli D, Lazzerini D, Cazzaniga S, Squicciarini P, Bignami P, Maier JAM, Sfondrini L, Menard S, Colnaghi MI, Balsari A: Evaluation of the balance between angiogenic and antiangiogenic circulating factors in patients with breast and gastrointestinal cancer. Clin Cancer Res 7:1221-1225, 1998

    Google Scholar 

  4. Folkman J: Tumor angiogenesis. In: Holland JF (ed) Cancer Medicine. Lea & Febiger, Melbourne PA, 1991, pp

    Google Scholar 

  5. Takei Y, Kurbone M, Uchida A, Hayashi K: Serum concentrations of basic fibroblast growth factor in breast cancer. Clin Chem 40:1980-1981, 1994

    Google Scholar 

  6. Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A, Mori T, Yoshida M, Ikeda T, Tominaga T: Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 2:821-826, 1996

    Google Scholar 

  7. Janeway CAJ, Travers P: The induction, measurement, and manipulation of the immune response. In: (eds) Immunobiology: The immune system in health and disease. Garland Publishing Inc, New York, 1997, pp 2:1-2:52

    Google Scholar 

  8. Hayes DF: Tumor markers for breast cancer: Current utilities and future prospects. In: Hayes DF (ed) Hematology/Oncology Clinics of North America: Tumor Markers in Adult Solid Malignancies. W.B. Saunders Co., Philadelphia, 1994, pp 485-506

    Google Scholar 

  9. ASCO Expert Panel: 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 16:793-795, 1998

    Google Scholar 

  10. ASCO Expert Panel: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer: Report of the American Society of Clinical Oncology expert panel. J Clin Oncol 14:2843-2877, 1996

    Google Scholar 

  11. Hayes DF, Trock B, Harris AL: Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful? Breast Cancer Res Treat 52:305-319, 1998 (this issue)

    Google Scholar 

  12. Schwartz MK: Circulating and tissue markers in the longitudinal management of breast cancer patients. Adv Exp Med Biol 353:47-53, 1994

    Google Scholar 

  13. Graves R, Hilgers J, Fritche H, Hayes DF, Robertson JFR: MUC-1 mucin assays for monitoring therapy in metastatic breast cancer. in press

  14. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987

    Google Scholar 

  15. Hayes DF, Cirrincione C, Carney W, Rodrigue S, Berry D, Younger J, Panasci L, Millard F, Duggan D, Henderson IC, Kufe DW: Elevated circulating HER-2/neu related protein (NRP) is associated with poor survival in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 12:58a, 1993

    Google Scholar 

  16. Leitzel K, Teramoto Y, Sampson E, Mauceri J, Langton BC, Demers L, Podczaski E, Harvey H, Shambaugh S, Volas G, Weaver S, Lipton A: Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 10:1436-1443, 1992

    Google Scholar 

  17. Hayes DF: Angiogenesis and breast cancer. In: Shapiro CL, Henderson IC (eds) Hematology/Oncology Clinics of North America. W.B. Saunders Co., Philadelphia, 1994, pp 51-71

    Google Scholar 

  18. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini N, Gaudino G, Tamagone L, Coffer A, Comoglio PM: Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119:629-641, 1992

    Google Scholar 

  19. Smith MEF, Thomas JA: Cellular expression of lymphocyte function associated antigens and the intercellular adhesion molecule-1 in normal tissue. J Clin Pathol 43:893-900, 1990

    Google Scholar 

  20. Kotch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ: Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 376:517-519, 1995

    Google Scholar 

  21. Westley BR, May FEB: Cathepsin D and breast cancer. Eur J Cancer 32A:15-24, 1995

    Google Scholar 

  22. Ossowsky L, Clunie G, Masucci MT, Blasi F: In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 115:1107-1112, 1991

    Google Scholar 

  23. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Hoyer-Hansen G, Ronne E, Dybkjaer E, Dano K, Brunner N: ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43:1868-1876, 1997

    Google Scholar 

  24. Meijer WG, van der Veer E, Willemse PH: Biochemical parameters of bone metabolism in bone metastases of solid tumors. Oncol Rep 5:5-21, 1998

    Google Scholar 

  25. Hayes DF: Serum tumor markers for breast cancer. In: Senn HJ (eds) Proceedings, 5th Annual Conference, Adjuvant Therapy in Primary Breast Cancer. Recent Results of Cancer Research. Springer-Verlag, Heidelberg, 1996, pp 101-113

    Google Scholar 

  26. Luthgens ML, Oher P: Clinical cancer markers: Diagnosis, prognosis, and monitoring. In: Sell S (ed) Serological Cancer Markers. Humana Press, Totowa NJ, 1992, pp 19-29

    Google Scholar 

  27. Smith TM, Lee MK, Szabo CI, Jerome N, McEuen M, Taylor M, Hood L, King MC: Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. Genome Res 6:1029-1049, 1996

    Google Scholar 

  28. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, et al: The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 12:333-337, 1996

    Google Scholar 

  29. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396, 1998

    Google Scholar 

  30. Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, Page D, Goodwin PJ: Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 47:111-120, 1998

    Google Scholar 

  31. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D: Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90:911-915, 1998

    Google Scholar 

  32. Eddy DM: Screening for breast cancer. Ann Int Med 111:389-399, 1989

    Google Scholar 

  33. Kerlikowske K: Efficacy of screening mammography among women aged 40 to 49 years and 50 to 69 years: comparison of relative and absolute benefit. J Natl Cancer Inst Monogr 22:79-86, 1997

    Google Scholar 

  34. Hare WS, Tjandra JJ, Russell IS, Collins JP, McKenzie IF: Comparison of mammary serum antigen assay with mammography in patients with breast cancer. Med J Aust 149:402-406, 1988

    Google Scholar 

  35. Ward BG, Joy GJ, Ramm LE, Baker CA, McGuckin MA: Comparative study of mammography and mammary serum antigen estimation for breast cancer screening. Med J Aust 157:161-164, 1992

    Google Scholar 

  36. Tondini C, Hayes DF, Kufe D: Circulating tumor markers in breast cancer. In: Henderson IC (ed) Diagnosis and Therapy of Breast Cancer. W.B. Saunders Co., Philadelphia, 1989, pp 653-674

    Google Scholar 

  37. Devine PL, Duroux MA, Quin RJ, McGuckin MA, Joy GJ, Ward BG, Pollard CW: CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer. Breast Cancer Res Treat 34:245-251, 1995

    Google Scholar 

  38. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA: High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15:3363-3367, 1997

    Google Scholar 

  39. Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J, Soussi T: Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 345:621-622, 1995

    Google Scholar 

  40. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T: The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52:6380-6384, 1992

    Google Scholar 

  41. Vojtesek B, Kovarik J, Dolezalova H, Nenutil R, Havlis P, Brentani RR, Lane DP: Absence of p53 autoantibodies in a significant proportion of breast cancer patients. Br J Cancer 71:1253-1256, 1995

    Google Scholar 

  42. Mudenda B, Green JA, Green B, Jenkins JR, Robertson L, Tarunina M, Leinster SJ: The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 69:1115-1119, 1994

    Google Scholar 

  43. Willsher PC, Pinder SE, Robertson L, Nicholson RI, Ellis IO, Bell JA, Blamey RW, Green JA, Robertson JF: The significance of p53 autoantibodies in the serum of patients with breast cancer. Anticancer Res 16:927-930, 1996

    Google Scholar 

  44. Gold P, Freedman S: Demonstration of tumor-specific antigens in human colonic carcinomata by immunologic tolerance and absorption techniques. J Exp Med 121:439-462, 1965

    Google Scholar 

  45. Chevinsky AH: CEA in tumors of other than colorectal origin. Semin Surg Oncol 7:162-166, 1991

    Google Scholar 

  46. Mazoujian G, Pinkus GS, Davis S, Haagensen DE Jr: Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast: a marker of apocrine epithelium and breast carcinomas with apocrine features. Am J Pathol 110:105-112, 1983

    Google Scholar 

  47. Cardoso de Almeida PC, Pestana CB: Immunohistochemical markers in the identification of metastatic breast cancer. Breast Cancer Res Treat 21:201-210, 1992

    Google Scholar 

  48. Haagensen D, Mazoujian G, Holder W, Kister S, Wells S: Evaluation of a breast cyst fluid protein detectable in the plasma of breast carcinoma patients. Ann Surg 185:279-285, 1977

    Google Scholar 

  49. Yu H, Levesque MA, Clark GM, Diamandis EP: Prognostic value of prostate-specific antigen for women with breast cancer: A large United States cohort study. Clin Cancer Res 4:1489-1497, 1998

    Google Scholar 

  50. Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Levesque MA, Diamandis EP: Prostate-specific antigen in serum of women with breast cancer. Br J Cancer 72:728-731, 1995

    Google Scholar 

  51. Isola J, Holli K, Oksa H, Teramoto Y, Kallioniemi O-P: Elevated erbB2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 73:652-658, 1994

    Google Scholar 

  52. Andersen TI, Paus E, Nesland JM, McKenzie SJ, Borresen AL: Detection of c-erbB-2 related protein in sera from breast cancer patients: Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. Acta Oncologica 34:499-504, 1995

    Google Scholar 

  53. Meden H, Marx D, Schauer A, Wuttke W, Kuhn W: Prognostic significance of p105 (c-erbB-2 HER2/neu) serum levels in patients with ovarian cancer. Anticancer Res 17:757-760, 1997

    Google Scholar 

  54. Sheen-Chen SM, Eng HL, Sheen CW, Cheng YF, Chou FF, Chen WJ: Serum levels of circulating intercellular adhesion molecule-1 in patients with breast cancer. Anticancer Res 17:2823-2826, 1997

    Google Scholar 

  55. Matsuura N, Narita T, Mitsuoka C, Kimura N, Kannagi R, Imai T, Funahashi H, Takagi H: Increased concentration of soluble E-selectin in the sera of breast cancer patients. Anticancer Res 17:1367-1372, 1997

    Google Scholar 

  56. Brouillet JP, Dufour F, Lemamy G, Garcia M, Schlup N, Grenier J, Mani JC, Rochefort H: Increased cathepsin D level in the serum of patients with metastatic breast carcinoma detected with a specific pro-cathepsin D immunoassay. Cancer 79:2132-2136, 1997

    Google Scholar 

  57. McGuire WL, Clark GM: Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 326:1756-1761, 1992

    Google Scholar 

  58. Robert J, Hoerni B: Age dependence of the early phase pharmacokinetics of doxorubicin. Cancer Res 43:4467-4469, 1983

    Google Scholar 

  59. Ciatto S, Pacini P, Azzini V, Neri A, Jannini A, Gosso P, Molino A, Capelli MC, di Costanzo F, Pucciatti MA, et al: Preoperative staging of primary breast cancer. A multicentric study. Cancer 61:1038-1040, 1988

    Google Scholar 

  60. Hayes DF, Zurawski VP Jr, Kufe DW: Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 4:1542-1550, 1986

    Google Scholar 

  61. Hayes DF, Henderson IC, Shapiro CL: Treatment of metastatic breast cancer: Present and future prospects. Semin Oncol 22:5-21, 1995

    Google Scholar 

  62. Colomer R, Ruibal A, Salvador L: Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 64:1674-1681, 1989

    Google Scholar 

  63. Bremer K, Eklund G, Bjorklund B: Notable relationship between the level of tumor marker TPS in serum and survival in breast cancer. Anticancer Res 16:905-909, 1996

    Google Scholar 

  64. Sledge G, Neuberg D, Ingle J, Martino S, Wood W: Phase III trial of doxorubicin vs. paclitaxel vs doxorubicin + paclitaxel as first line therapy for metastatic breast cancer: An Intergroup trial. Proc Am Soc Clin Oncol 16:1a, 1997

    Google Scholar 

  65. Colomer R, Aparicio J, Montero S, Guzman C, Larrodera L, Cortes-Funes H: Low levels of basic fibroblast growth factor (bFGF) are associated with a poor prognosis in human breast carcinoma. Br J Cancer 76:1215-1220, 1997

    Google Scholar 

  66. Sliutz G, Tempfer C, Obermair A, Dadak C, Kainz C: Serum evaluation of basic FGF in breast cancer patients. Anticancer Res 15:2675-2677, 1995

    Google Scholar 

  67. Taniguchi T, Toi M, Inada K, Imazawa T, Yamamoto Y, Tominaga T: Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin Cancer Res 1:1031-1034, 1995

    Google Scholar 

  68. Toi M, Taniguchi T, Ueno T, Asano M, Funata N, Sekiguchi K, Iwanari H, Tominaga T: Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin Cancer Res 4:659-664, 1998

    Google Scholar 

  69. Maemura M, Iino Y, Yokoe T, Horiguchi J, Takei H, Koibuchi Y, Horii Y, Takeyoshi I, Ohwada S, Morishita Y: Serum concentration of hepatocyte growth factor in patients with metastatic breast cancer. Cancer Lett 126:215-220, 1998

    Google Scholar 

  70. Foekens JA, Schmitt M, van Putten WL, Peter HA, Bontenbal M, Janicke F, Klijn JG: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52:6101-6105. 1992

    Google Scholar 

  71. Duggan C, Maguire T, McDermott E, O'Higgins N, Fennelly JJ, Duffy MJ: Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 61:597-600, 1995

    Google Scholar 

  72. Hebbar M, Revillion F, Louchez MM, Vilain MO, Fournier C, Bonneterre J, Peyrat JP: The relationship between concentrations of circulating soluble E-selectin and clinical, pathological, and biological features in patients with breast cancer. Clin Cancer Res 4:373-380, 1998

    Google Scholar 

  73. Osborne RJ, Merlo GR, Mitsudomi T, Venesio T, Liscia DS, Cappa AP, Chiba I, Takahashi T, Nau MM, Callahan R, et al: Mutations in the p53 gene in primary human breast cancers. Cancer Res 51:6194-6198, 1991

    Google Scholar 

  74. Lowe SW, Bodis S, McClatchey A: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994

    Google Scholar 

  75. Kandioler-Eckersberger D, Taucher B, Steiner M, Udas M, Mannhalter C, Steger G, Jakesz R: P53 genotype and major response to anthracycline or paclitaxel based neoadjuvant treatment in breast cancer patients. Proc Am Soc Clin Oncol 17:102a (abstr 392), 1998

    Google Scholar 

  76. McGuire WL: Breast cancer prognostic factors: Evaluation guidelines. J Natl Cancer Inst 83:154-155, 1991

    Google Scholar 

  77. Hayes DF: Should we treat HER, too? J Clin Oncol 14:697-699, 1996

    Google Scholar 

  78. Gaasparini G, Harris A: Clinical importance of the determination of tumor angiogenesis in breast carcinoma: Much more than a new prognostic tool. J Clin Oncol 13:7652-7682, 1995

    Google Scholar 

  79. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, et al: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10:1049-1056, 1992

    Google Scholar 

  80. Muss HB, Thor A, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: c-erbB-2 expression and Sphase activity predict response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994

    Google Scholar 

  81. Colomer R, Montere S, Lluch A, Ojeda B, Barnadas A, Martin M, Massuti B, Cortes-Funes H, Vega F, Benito M: Circulating HER-2/neu predicts resistance to Taxol/Adriamycin in metastatic breast carcinoma: Preliminary results of a multicentric study. Proc Am Soc Clin Oncol 16:140a, 1997

    Google Scholar 

  82. Stender MJ, Neuberg D, Wood W, Sledge G: Correlation of circulating c-erb B-2 extracellular domain (Her-2) with clinical outcome in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 16:154a (abstr 541), 1997

    Google Scholar 

  83. Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H, Harvey H, Demers L, Lipton A: Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13:1129-1135, 1995

    Google Scholar 

  84. Yamauchi H, O'Neill A, Gelman R, Carney W, Hosch S, Hayes DF: Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15:2518-2525, 1997

    Google Scholar 

  85. Fehm T, Maimonis P, Katalinic A, Jager WH: The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology 55:33-38, 1998

    Google Scholar 

  86. Harris LN, Trock B, Berris M, Esteva-Lorenzo F, Paik S: The role of ERBB2 extracellular domain in predicting response to chemotherapy in breast cancer patients. Proc Am Soc Clin Oncol 15:108a, 1996

    Google Scholar 

  87. Fehm T, Maimonis P, Weitz S, Teramoto Y, Katalinic A, Jager W: Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 43:87-95, 1997

    Google Scholar 

  88. Baselga J, Seidman AD, Rosen PP, Norton L: HER2 overexpression and paclitaxel sensitivity in breast cancer: Therapeutic implications. Oncology 11:43-48, 1997

    Google Scholar 

  89. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz C, Dantis L, Sklarin N, Seidman A, Hudis C, Moore J, Rosen P, Twaddell T, Henderson IC, Norton L: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996

    Google Scholar 

  90. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Paton V, Shak S, Lieberman G, Slamon D: Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 17:97a(abstr 376), 1998

    Google Scholar 

  91. Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Baselga J, Norton L: Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized multinational controlled phase III trial. Proc Am Soc Clin Oncol 17:98a (abstr 377), 1998

    Google Scholar 

  92. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998

    Google Scholar 

  93. Foekens JA, Look MP, Peters HA, van Putten WL, Portengen H, Klijn JG: Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 87:751-756, 1995

    Google Scholar 

  94. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomized trials. Lancet 351:1451-1467, 1998

    Google Scholar 

  95. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71–85, 1992

    Google Scholar 

  96. GIVIO Investigators: Impact of follow-up and testing on survival and health-related quality of life in breast cancer patients: A multicenter randomized controlled trial. J Am Med Assoc 271:1587-1593, 1994

    Google Scholar 

  97. Rosselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P, Distante V: Intensive diagnostic follow-up after treatment of primary breast cancer: A randomized trial. J Am Med Assoc 271:1593-1597, 1994

    Google Scholar 

  98. Molina R, Zanon G, Filella X, Moreno F, Jo J, Daniels M, Latre ML, Gimenez N, Pahisa J, Velasco M, et al: Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 36:41-48, 1995

    Google Scholar 

  99. Molina R, Jo J, Zanon G, Filella X, Farrus B, Munoz M, Latre M, Pahisa J, Valasco M, Fernandez P, Estape J, Ballesta A: Utility of c-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA15.3. Br J Cancer 74:1126-1131, 1996

    Google Scholar 

  100. Kovner F, Merimsky O, Hareuveni M, Wigler N, Chaitchik S: Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial. Cancer Chemother Pharmacol 35:80-83, 1994

    Google Scholar 

  101. Hayes DF, Zurawski V, Kufe DW: Comparison of circulating breast cancer associated antigen CA15-3 with CEA in patients with breast cancer. Proc Am Soc Clin Oncol 5:12a, 1986

    Google Scholar 

  102. Tondini C, Hayes DF, Gelman R, Henderson IC, Kufe DW: Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 48:4107-4112, 1988

    Google Scholar 

  103. Willsher PC, Beaver J, Blamey RW, Robertson JF: Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: Comparison with CA 15.3 and CEA. Anticancer Res 15:1609-1611, 1995

    Google Scholar 

  104. Schuurman JJ, Bong SB, Einarsson R: Determination of serum tumor markers TPS and CA 15-3 during monitoring of treatment in metastatic breast cancer patients. Anticancer Res 16:2169-2172, 1996

    Google Scholar 

  105. Soletormos G, Nielsen D, Schioler V, Skovsgaard T, Dombernowsky P: Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Clin Chem 42:564-575, 1996

    Google Scholar 

  106. Hayes DF, Kiang DT, Korzun A, Tondini C, Wood W, Kufe D: CA15-3 and CEA spikes during chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 7:38a, 1988

    Google Scholar 

  107. Eisen T, Boshoff C, Vaughan MM, Pyle L, Smith IE, Johnston SRD, Bunker C, Kitchen P, Rowe A, Gore ME: Anti-angiogenic treatment of metastatic melanoma, renal cell, ovarian and breast cancer with thalidomide: A phase II study. Proc Am Soc Clin Oncol 17:441a(abstr 1699), 1998

    Google Scholar 

  108. Chan D, Beveridge R, Muss H, Fritsche H, Hortobagyi G, Theriault R, Kiang D, Kennedy BJ, Evelegh M: Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 15:2322-2328, 1997

    Google Scholar 

  109. Pavesi F, Lotzniker M, Scarabelli M, Mauro E, Visconti G, Nicolato E, Moratti R: Circulating CA 549 and other associated antigens in breast cancer patients. Oncology 51:18-21, 1994

    Google Scholar 

  110. Donadeo A, Micelli G, Quaranta M, Atlantc A, Schittulli F: MCA performance in preoperative breast cancer patients. Anticancer Res 15:527-529, 1995

    Google Scholar 

  111. Willsher PC, Beaver J, Pinder S, Bell JA, Ellis IO, Blamey RW, Robertson JF: Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 40:251-255, 1996

    Google Scholar 

  112. Dirix LY, Vermeulen PB, Pawinski A, Prove A, Benoy I, De Pooter C, Martin M, Van Oosterom AT: Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 76:238-243, 1997

    Google Scholar 

Download references

Authors
  1. Vered Stearns
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hideko Yamauchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel F. Hayes
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stearns, V., Yamauchi, H. & Hayes, D.F. Circulating tumor markers in breast cancer: Accepted utilities and novel prospects. Breast Cancer Res Treat 52, 239–259 (1998). https://doi.org/10.1023/A:1006137619153

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006137619153

Search

Navigation